- Home
- SKIN vs IVA Comparison
SKIN vs IVA Comparison
Compare SKIN & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKIN
- IVA
- Stock Information
- Founded
- SKIN 1997
- IVA 2011
- Country
- SKIN United States
- IVA France
- Employees
- SKIN N/A
- IVA N/A
- Industry
- SKIN Package Goods/Cosmetics
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- SKIN Consumer Discretionary
- IVA Health Care
- Exchange
- SKIN Nasdaq
- IVA Nasdaq
- Market Cap
- SKIN 164.1M
- IVA 162.8M
- IPO Year
- SKIN N/A
- IVA 2020
- Fundamental
- Price
- SKIN $1.23
- IVA $2.94
- Analyst Decision
- SKIN Hold
- IVA Strong Buy
- Analyst Count
- SKIN 5
- IVA 4
- Target Price
- SKIN $2.50
- IVA $13.25
- AVG Volume (30 Days)
- SKIN 648.4K
- IVA 7.6K
- Earning Date
- SKIN 03-12-2025
- IVA 03-26-2025
- Dividend Yield
- SKIN N/A
- IVA N/A
- EPS Growth
- SKIN N/A
- IVA N/A
- EPS
- SKIN N/A
- IVA N/A
- Revenue
- SKIN $334,294,000.00
- IVA $15,243,814.00
- Revenue This Year
- SKIN $1.93
- IVA $18.05
- Revenue Next Year
- SKIN $12.41
- IVA $46.74
- P/E Ratio
- SKIN N/A
- IVA N/A
- Revenue Growth
- SKIN N/A
- IVA N/A
- 52 Week Low
- SKIN $0.91
- IVA $1.53
- 52 Week High
- SKIN $4.23
- IVA $3.98
- Technical
- Relative Strength Index (RSI)
- SKIN 38.14
- IVA 52.48
- Support Level
- SKIN $1.25
- IVA $2.88
- Resistance Level
- SKIN $1.39
- IVA $3.10
- Average True Range (ATR)
- SKIN 0.11
- IVA 0.18
- MACD
- SKIN 0.00
- IVA -0.02
- Stochastic Oscillator
- SKIN 2.86
- IVA 54.55
About SKIN The Beauty Health Company
The Beauty Health Co is a category-creating beauty health company that along with its subsidiaries designs, develops, manufactures, markets and sells esthetic technologies and products. The company's brand portfolio includes Hydrafacial, SkinStylus, and Keravive, offering Syndeo device, SkinStylus SteriLock Microsystem, Keravive Peptide Solution and other products.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.